Epithelial-Mesenchymal Transition-Mediated Tumor Therapeutic Resistance

Molecules. 2022 Jul 25;27(15):4750. doi: 10.3390/molecules27154750.

Abstract

Cancer is one of the world's most burdensome diseases, with increasing prevalence and a high mortality rate threat. Tumor recurrence and metastasis due to treatment resistance are two of the primary reasons that cancers have been so difficult to treat. The epithelial-mesenchymal transition (EMT) is essential for tumor drug resistance. EMT causes tumor cells to produce mesenchymal stem cells and quickly adapt to various injuries, showing a treatment-resistant phenotype. In addition, multiple signaling pathways and regulatory mechanisms are involved in the EMT, resulting in resistance to treatment and hard eradication of the tumors. The purpose of this study is to review the link between EMT, therapeutic resistance, and the molecular process, and to offer a theoretical framework for EMT-based tumor-sensitization therapy.

Keywords: EMT; chemoresistance; immunity therapy; radioresistance; targeted therapy.

Publication types

  • Review

MeSH terms

  • Drug Resistance, Neoplasm
  • Epithelial-Mesenchymal Transition*
  • Humans
  • Neoplasms* / metabolism
  • Neoplastic Stem Cells / metabolism
  • Signal Transduction